The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. (2014)

First Author: Backen A
Attributed to:  Infrastructure for collaboration: Leeds MRC Medical Bioinformatics Centre funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/1078-0432.ccr-13-3248

PubMed Identifier: 24947924

Publication URI: http://europepmc.org/abstract/MED/24947924

Type: Journal Article/Review

Volume: 20

Parent Publication: Clinical cancer research : an official journal of the American Association for Cancer Research

Issue: 17

ISSN: 1078-0432